Abstract
1119 Background: Testing for BRCA1 and BRCA2 mutations in breast cancer patients is used to identify risk of second primary cancers and risk of cancer in the patients’ family. A high proportion of BRCA1 mutation positive patients have triple-negative breast cancer (TNBC). TNBC shows a poor prognosis and no effective treatment strategies against TNBC are available to date. However, BRCA-related cancers are sensitive to platinum chemotherapy as well as to drugs targeting poly (ADP-ribose) polymerase enzymes, which are under development so far. Women with TNBC are thought to be more likely to be BRCA mutation carriers, but there have only been limited numbers of studies investigating BRCA1- and BRCA2-mutation status among Caucasian patients with TNBC. Methods: We determined the prevalence of BRCA1 and BRCA2 mutations within a cohort of 88 unselected TNBC cases including patients from Germany and Austria. Double-stranded Sanger sequencing of all exons of BRCA1 and BRCA2, respectively, was performed. Results: ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
